Archive for the 'Provigil @ Google News' Category

Ranbaxy Falls Most Since March on Proposed Settlement Costs: Mumbai Mover – Bloomberg


Bloomberg
Ranbaxy Falls Most Since March on Proposed Settlement Costs: Mumbai Mover
Bloomberg
Provigil, Diovan Near-term exclusivities relate to versions of the sleep- disorder drug Provigil, which had $1.1 billion in sales in 2010; Actos; and Diovan, a blood-pressure pill made by Novartis AG (NOVN) that generated $1.5 billion in annual sales,
Share market, analysts give Ranbaxy a thumbs downBusiness Standard
Ranbaxy falls 7% to nine-month low on USFDA settlement costsEconomic Times
Tough US strictures on RanbaxyCalcutta Telegraph
Times of India -Hindu Business Line
all 154 news articles »

Ranbaxy Falls Most Since March on Proposed Settlement Costs: Mumbai Mover – Bloomberg


Bloomberg
Ranbaxy Falls Most Since March on Proposed Settlement Costs: Mumbai Mover
Bloomberg
Provigil, Diovan Near-term exclusivities relate to versions of the sleep- disorder drug Provigil, which had $1.1 billion in sales in 2010; Actos; and Diovan, a blood-pressure pill made by Novartis AG (NOVN) that generated $1.5 billion in annual sales,
Share market, analysts give Ranbaxy a thumbs downBusiness Standard
Ranbaxy falls 7% to nine-month low on USFDA settlement costsEconomic Times
Ranbaxy scrip tanks 7% on 'harsh settlement' in USTimes of India
Calcutta Telegraph -Hindu Business Line
all 154 news articles »

Sell Ranbaxy Labs; target of Rs 355: PINC Research – Moneycontrol.com


Moneycontrol.com
Sell Ranbaxy Labs; target of Rs 355: PINC Research
Moneycontrol.com
Although the names of FTFs surrendered have not been disclosed, we expect it to be generic Provigil, Diovan and Valcyte contributing sales to the tune of USD186mn and NPV of Rs12 per share. The stock is currently trading at 29.2x and 20.3x its CY12E

and more »

Don’t get excited about pharma cos with USFDA issues: IIFL – Moneycontrol.com

Don't get excited about pharma cos with USFDA issues: IIFL
Moneycontrol.com
The Department of Justice has not revealed which are those exclusivities, but I believe one of them could be Provigil, the other two could be smaller ones. For most of the larger exclusivities, which are Nexium Actos and Valsartan, I believe the FDA

and more »